In February 2022, the FDA approved ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy.
March 4th 2022, 7:00pm
In an interview with CancerNetwork®, Thomas G. Martin spoke about how the approval of ciltacabtagene autoleucel will likely dramatically impact the standard of care for patients with relapsed/refractory multiple myeloma.
March 1st 2022, 3:09am
Patients with multiple myeloma may now receive treatment with ciltacabtagene autoleucel following its approval by the FDA.
March 5th 2022
March 3rd 2022